Trials / Completed
CompletedNCT04736134
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Administration of BMS-986326 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, drug effects, and immunogenicity of BMS-986326 after infusion or injection in healthy participants. The results of this study will guide the selection of the dose range, dosing frequency, and the route of administration for future studies of BMS-986326 in participants with immune-mediated diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986326 | Specified dose on specified days |
| OTHER | Placebo matching BMS-986326 | Specified dose on specified days |
| BIOLOGICAL | Multiple Ascending Dose SC | Specified dose on specified days |
| OTHER | Multiple Ascending Dose Placebo | Specified dose on specified days |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2024-03-14
- Completion
- 2024-03-14
- First posted
- 2021-02-03
- Last updated
- 2024-05-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04736134. Inclusion in this directory is not an endorsement.